Cancer Immunotherapy
Immune Suppression and Tumor Growth
2nd Edition
Published on 29. July 2013
Book
Hardback
684 pages
978-0-12-394296-8 (ISBN)
Description
There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers with an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease.
Reviews / Votes
"...an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease." --Anticancer Research, January 2015"Prendergast... and Jaffee...supply basic, translational, and clinical cancer researchers in immunology, biology, and pharmacology with 34 chapters on immunotherapy in cancer treatments. They address new principles of immune suppression in cancer and recent thinking in how immunotherapeutic and chemotherapeutic agents might be combined to defeat mechanisms of tumoral immune suppression and reprogram the inflammatory microenvironment of tumor cells to enhance long-term outcomes." --Reference and Research Book News, December 2013
More details
Edition
2nd edition
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
Basic, translational, and clinical cancer researchers as well as practicing oncologists and their patients
Product notice
sewn/stitched
Paper over boards
Illustrations
Illustrated
Dimensions
Height: 287 mm
Width: 222 mm
Thickness: 43 mm
Weight
2098 gr
ISBN-13
978-0-12-394296-8 (9780123942968)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
E-Book
06/2013
2nd Edition
Academic Press
€97.95
Available for download
Previous edition
Book
08/2007
Academic Press
€95.48
Article exhausted; check for reprint
Persons
Dr. Prendergast is an international leader in basic and preclinical biomedical research, with deep expertise in the discovery and development of molecular therapies for cancer and other chronic diseases. A scientist and inventor, he is widely recognized for translating laboratory discoveries into practical medical innovations and for founding and advising multiple biomedical startup companies. He has led major advances in cancer immunotherapy, including pioneering work on IDO inhibition and the development of cryoimmune vaccination strategies to address drug-resistant metastatic disease. Formerly Editor-in-Chief of Cancer Research, he has played a significant role in shaping the field's scientific direction. As President and CEO of LIMR, Dr. Prendergast established the acapreneurial (TM) model, integrating nonprofit research with entrepreneurial biotechnologies to accelerate clinical impact, societal benefit, and sustainable innovation.
Content
Part I: Principles of Cancer ImmunobiologyIntroductionCancer Immunoediting: From Immune Surveillance to Immune EscapeImmunosurveillance: Innate and Adaptive Anti-Tumor ImmunityCytokine Regulation of Immune Tolerance to TumorsImmunological Sculpting: Natural Killer Cell Receptors and LigandsImmune Escape: Immunosuppressive NetworksPart II: Cancer TherapeuticsCytotoxic Chemotherapy in Clinical Treatment of CancerTargeted Therapeutics in Cancer TreatmentConcepts in Pharmacology and ToxicologyCancer Immunotherapy: Challenges and OpportunitiesCancer VaccinesPart III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune SuppressionImmunotherapy and Cancer Therapeutics: Why Partner?Immune Stimulatory Features of Classical ChemotherapyDendritic Cells and Co-Inhibitory MoleculesRegulatory T Cells in Tumor Immunity: Role of Toll-like Receptors Tumor-associated Macrophages in Cancer Growth and ProgressionTumor-associated Myeloid-derived Suppressor CellsProgrammed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune EscapeIDO in Immune Escape: Regulation and Therapeutic InhibitionArginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune ModulationSummary: Future Questions